NATriuretic Response to Expansion and dIUretics in huMans With Heart Failure
Status:
Not yet recruiting
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
NATRIUM-HF is a multicenter, non-randomized, pre-post intervention study designed to assess
renal response to intravascular fluid expansion and diuretics after sacubitril/valsartan
(Entresto®) in euvolemic heart failure patients with reduced ejection fraction. Approximately
230 eligible patients will attend one visit prior to and visits 2 and 3 months after starting
Entresto®. At each visit, the patient's responses to extravascular fluid expansion with
Ringer's solution and to a loop diuretic bolus will be measured. Biomarkers measured in blood
and urine samples will include natriuretic peptides (NP) B-type NP (BNP) and N-terminal
proBNP (NT-proBNP), NP fragments, neprilysin activity and concentration, and other biomarkers
related to heart failure.
Phase:
N/A
Details
Lead Sponsor:
Momentum Research, Inc.
Collaborators:
Abbott Saint-Louis-Lariboisière University Hospitals